Last reviewed · How we verify

Carbaphen (PHENICARBAZIDE)

FDA-approved withdrawn Small molecule Quality 15/100

Carbaphen, marketed as Phenicarbazide, is an anti-allergenic drug primarily indicated for allergic rhinitis. Its key strength lies in its mechanism of action, which effectively modulates the body's response to allergens and irritants, reducing inflammation and congestion in the nasal passages. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic namePHENICARBAZIDE
Drug classphenicarbazide
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: